Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND
Summary
Every financing decision we make is grounded in a long-term view of shareholder value, and this raise reflects that discipline.From an operational standpoint, our first goal is to submit our IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way. We believe pursuing a rare disease indication gives us a strategic entry point to demonstrate clinical impact and build broader value.Telomir is advancing two highly innovative drug candidates: Telomir-1, a first-in-class age-reversal molecule targeting the root causes of cellular decline, and Telomir-Ag2, a stabilized Silver(II) compound designed to address the growing threat of drug-resistant infections.Telomir-1 is an oral small molecule that addresses five fundamental biological drivers of aging and chronic disease: mitochondrial dysfunction, oxidative stress, calcium imbalance, toxic metal accumulation (iron and copper), and telomere shortening. Reversal of the biological clock, improving both lifespan and health span Correction of calcium signaling pathways associated with neurodegeneration and cell death Protection against metal-induced toxicity from iron and copperTherapeutic potential has been demonstrated across several critical indications: Progeria: Telomir confirms lifespan restoration and normalization of accelerated aging in a preclinical model of Progeria, a rare genetic disorder causing rapid aging Chemotherapy support: Co-administration with Paclitaxel prevented mortality in animals otherwise experiencing toxicity Retinal and neural protection: In vitro studies showed strong protection of human retinal cells from oxidative and metal stress conditionsThese results support the advancement of Telomir-1 in multiple rare and high-value indications, including:Telomir plans to engage with the FDA through the Rare Disease Endpoint Advancement (RDEA) Pilot Program, which supports the development of novel clinical endpoints for underserved conditions. In parallel, the Company is advancing a rare disease indication aligned with Telomir-1s mechanism of action to efficiently generate early human efficacy data and support broader clinical development.Telomir-Ag2 is a novel Silver(II) complex stabilized using Telomirs proprietary chelation platform. Silver(II) has historically shown strong antimicrobial potential but has remained clinically impractical due to its instability-until now.Preclinical studies demonstrate that Telomir-Ag2 is active against: Broad potential as a topical product across burn treatment, wound care, and surgical infection preventionTelomir-Ag2 addresses a growing global market projected to exceed $30 billion across antimicrobial dressings, hospital-acquired infection prevention, and wound care.Telomir-Ag2 may be the first stabilized Silver(II) compound viable for medical use, said Dr. Itzchak Angel, Chief Scientific Advisor of the Company.